vs
华钦科技（CLPS）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是华钦科技的1.5倍（$127.1M vs $82.8M）
华钦科技（CLPS Inc）是全球领先的信息技术咨询与数字化解决方案服务商，核心服务银行、保险、资产管理等金融领域客户，同时覆盖零售、医疗健康、电商等行业，业务遍及北美、亚太及欧洲地区。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
CLPS vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.5倍
$82.8M
损益表 — Q4 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $82.8M | $127.1M |
| 净利润 | $183.0K | — |
| 毛利率 | 23.1% | 51.0% |
| 营业利润率 | 0.2% | -54.6% |
| 净利率 | 0.2% | — |
| 营收同比 | — | 17.1% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | — | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLPSZLAB
| Q2 26 | $82.8M | — | ||
| Q4 25 | — | $127.1M | ||
| Q3 25 | — | $115.4M | ||
| Q2 25 | — | $109.1M | ||
| Q1 25 | — | $105.7M | ||
| Q4 24 | $71.8M | $108.5M | ||
| Q3 24 | — | $101.8M | ||
| Q2 24 | — | $100.1M |
净利润CLPSZLAB
| Q2 26 | $183.0K | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $-36.0M | ||
| Q2 25 | — | $-40.7M | ||
| Q1 25 | — | $-48.4M | ||
| Q4 24 | $-993.5K | — | ||
| Q3 24 | — | $-41.7M | ||
| Q2 24 | — | $-80.3M |
毛利率CLPSZLAB
| Q2 26 | 23.1% | — | ||
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | 21.9% | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% |
营业利润率CLPSZLAB
| Q2 26 | 0.2% | — | ||
| Q4 25 | — | -54.6% | ||
| Q3 25 | — | -42.3% | ||
| Q2 25 | — | -50.3% | ||
| Q1 25 | — | -53.3% | ||
| Q4 24 | -1.3% | -62.6% | ||
| Q3 24 | — | -66.6% | ||
| Q2 24 | — | -76.0% |
净利率CLPSZLAB
| Q2 26 | 0.2% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | -31.2% | ||
| Q2 25 | — | -37.3% | ||
| Q1 25 | — | -45.8% | ||
| Q4 24 | -1.4% | — | ||
| Q3 24 | — | -40.9% | ||
| Q2 24 | — | -80.2% |
每股收益（稀释后）CLPSZLAB
| Q2 26 | — | — | ||
| Q4 25 | — | $-0.05 | ||
| Q3 25 | — | $-0.03 | ||
| Q2 25 | — | $-0.04 | ||
| Q1 25 | — | $-0.04 | ||
| Q4 24 | — | $-0.09 | ||
| Q3 24 | — | $-0.04 | ||
| Q2 24 | — | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $29.1M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $57.6M | $715.5M |
| 总资产 | $118.1M | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CLPSZLAB
| Q2 26 | $29.1M | — | ||
| Q4 25 | — | $689.6M | ||
| Q3 25 | — | $717.2M | ||
| Q2 25 | — | $732.2M | ||
| Q1 25 | — | $757.3M | ||
| Q4 24 | $31.2M | $779.7M | ||
| Q3 24 | — | $616.1M | ||
| Q2 24 | — | $630.0M |
股东权益CLPSZLAB
| Q2 26 | $57.6M | — | ||
| Q4 25 | — | $715.5M | ||
| Q3 25 | — | $759.9M | ||
| Q2 25 | — | $791.7M | ||
| Q1 25 | — | $810.8M | ||
| Q4 24 | $63.9M | $840.9M | ||
| Q3 24 | — | $667.7M | ||
| Q2 24 | — | $704.2M |
总资产CLPSZLAB
| Q2 26 | $118.1M | — | ||
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | $110.0M | $1.2B | ||
| Q3 24 | — | $985.3M | ||
| Q2 24 | — | $987.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | — | $-26.7M |
| 自由现金流率自由现金流/营收 | — | -21.0% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-158.9M |
8季度趋势，按日历期对齐
经营现金流CLPSZLAB
| Q2 26 | — | — | ||
| Q4 25 | — | $-26.0M | ||
| Q3 25 | — | $-32.0M | ||
| Q2 25 | — | $-31.0M | ||
| Q1 25 | — | $-61.7M | ||
| Q4 24 | — | $-55.8M | ||
| Q3 24 | — | $-26.8M | ||
| Q2 24 | — | $-42.2M |
自由现金流CLPSZLAB
| Q2 26 | — | — | ||
| Q4 25 | — | $-26.7M | ||
| Q3 25 | — | $-35.0M | ||
| Q2 25 | — | $-33.9M | ||
| Q1 25 | — | $-63.2M | ||
| Q4 24 | — | $-58.4M | ||
| Q3 24 | — | $-28.2M | ||
| Q2 24 | — | $-42.9M |
自由现金流率CLPSZLAB
| Q2 26 | — | — | ||
| Q4 25 | — | -21.0% | ||
| Q3 25 | — | -30.4% | ||
| Q2 25 | — | -31.1% | ||
| Q1 25 | — | -59.9% | ||
| Q4 24 | — | -53.8% | ||
| Q3 24 | — | -27.7% | ||
| Q2 24 | — | -42.9% |
资本支出强度CLPSZLAB
| Q2 26 | — | — | ||
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 1.5% | ||
| Q4 24 | — | 2.4% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 0.7% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CLPS
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
